These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 30516575)

  • 1. Effectiveness of Venlafaxine in Selective Serotonin Reuptake Inhibitor-Resistant Obsessive-Compulsive Disorder: Experience From a Specialty Clinic in India.
    Balachander S; Kodancha PG; Arumugham SS; Sekharan JT; Narayanaswamy JC; Reddy YCJ
    J Clin Psychopharmacol; 2019; 39(1):82-85. PubMed ID: 30516575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Risperidone Augmentation in Obsessive-Compulsive Disorder: Experience From a Specialty Clinic in India.
    Hegde A; Kalyani BG; Arumugham SS; Narayanaswamy JC; Math SB; Reddy YC
    J Clin Psychopharmacol; 2016 Aug; 36(4):381-4. PubMed ID: 27219093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder.
    Denys D; van der Wee N; van Megen HJ; Westenberg HG
    J Clin Psychopharmacol; 2003 Dec; 23(6):568-75. PubMed ID: 14624187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial.
    Denys D; Van Nieuwerburgh F; Deforce D; Westenberg HG
    J Clin Psychiatry; 2007 May; 68(5):747-53. PubMed ID: 17503984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study.
    Albert U; Aguglia E; Maina G; Bogetto F
    J Clin Psychiatry; 2002 Nov; 63(11):1004-9. PubMed ID: 12444814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review.
    Dell'Osso B; Nestadt G; Allen A; Hollander E
    J Clin Psychiatry; 2006 Apr; 67(4):600-10. PubMed ID: 16669725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aripiprazole augmentation in highly treatment-resistant obsessive-compulsive disorder - experience from a specialty clinic in India.
    Hegde A; Kalyani BG; Arumugham SS; Narayanaswamy JC; Math SB; Reddy YC
    Int J Psychiatry Clin Pract; 2017 Mar; 21(1):67-69. PubMed ID: 27629160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.
    Albert U; Marazziti D; Di Salvo G; Solia F; Rosso G; Maina G
    Curr Med Chem; 2018; 25(41):5647-5661. PubMed ID: 29278206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder.
    Hood SD; Broyd A; Robinson H; Lee J; Hudaib AR; Hince DA
    J Psychopharmacol; 2017 Dec; 31(12):1615-1623. PubMed ID: 29095069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.
    Storch EA; Goddard AW; Grant JE; De Nadai AS; Goodman WK; Mutch PJ; Medlock C; Odlaug B; McDougle CJ; Murphy TK
    J Clin Psychiatry; 2013 Jun; 74(6):e527-32. PubMed ID: 23842022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series.
    Dell'osso B; Mundo E; Marazziti D; Altamura AC
    J Psychopharmacol; 2008 Mar; 22(2):210-3. PubMed ID: 18208931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of venlafaxine in the treatment of obsessive-compulsive disorder.
    Phelps NJ; Cates ME
    Ann Pharmacother; 2005 Jan; 39(1):136-40. PubMed ID: 15585743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
    Costa DLC; Diniz JB; Requena G; Joaquim MA; Pittenger C; Bloch MH; Miguel EC; Shavitt RG
    J Clin Psychiatry; 2017 Jul; 78(7):e766-e773. PubMed ID: 28617566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venlafaxine in treatment-resistant obsessive-compulsive disorder.
    Hollander E; Friedberg J; Wasserman S; Allen A; Birnbaum M; Koran LM
    J Clin Psychiatry; 2003 May; 64(5):546-50. PubMed ID: 12755657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic study.
    Tundo A; Salvati L; Busto G; Di Spigno D; Falcini R
    J Clin Psychiatry; 2007 Oct; 68(10):1552-6. PubMed ID: 17960971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder.
    Denys D; van Megen HJ; van der Wee N; Westenberg HG
    J Clin Psychiatry; 2004 Jan; 65(1):37-43. PubMed ID: 14744166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of SLC1A1 gene polymorphism with obsessive compulsive disorder in a sample from southern India.
    Shukla T; Nadella RK; Taj M J RJ; Ganesh S; Nestadt G; Purushottam M; Jain S; Reddy YCJ; Viswanath B
    Exp Clin Psychopharmacol; 2020 Dec; 28(6):617-621. PubMed ID: 31985241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: improvement with treatment and worsening following discontinuation.
    Pallanti S; Bernardi S; Antonini S; Singh N; Hollander E
    Eur Neuropsychopharmacol; 2014 Mar; 24(3):375-80. PubMed ID: 24406025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis.
    Issari Y; Jakubovski E; Bartley CA; Pittenger C; Bloch MH
    J Clin Psychiatry; 2016 May; 77(5):e605-11. PubMed ID: 27249090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.